Patent · US Active

Influenza virus hemagglutinin mutants

US12428661B2 · kind B2 · utility

0Cited by
0References
16Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 27, 2019
Grant dateSep 30, 2025
Priority date
Expiry dateApr 15, 2042

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2760/16152
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to the production of modified influenza vial proteins in plants. More specifically, the present invention relates to producing and increasing influenza virus-like particle (VLP) production in plants, wherein the VLPs comprise the modified influenza viral proteins, such as modified influenza hemagglutinin (HA). The HA protein may comprising an amino acid sequence comprising at least one substitution when compared to a corresponding wildtype amino acid sequence. Further provided are nucleic acid encoding the modified HA protein. Furthermore methods of producing an influenza virus like particle (VLP) and methods of increasing yield of production of an influenza virus like particle (VLP) in a plant, portion of a plant, or a plant cell, are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.